1001 related articles for article (PubMed ID: 36648330)
1. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
2. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
[TBL] [Abstract][Full Text] [Related]
3. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.
Fisher FM; Chui PC; Nasser IA; Popov Y; Cunniff JC; Lundasen T; Kharitonenkov A; Schuppan D; Flier JS; Maratos-Flier E
Gastroenterology; 2014 Nov; 147(5):1073-83.e6. PubMed ID: 25083607
[TBL] [Abstract][Full Text] [Related]
5. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
6. Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity.
Kim MB; Bae M; Lee Y; Kang H; Hu S; Pham TX; Park YK; Lee JY
Nutrients; 2022 May; 14(11):. PubMed ID: 35684079
[TBL] [Abstract][Full Text] [Related]
7. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
[TBL] [Abstract][Full Text] [Related]
8. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
9. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
10. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
[TBL] [Abstract][Full Text] [Related]
11. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.
Yano K; Yamaguchi K; Seko Y; Okishio S; Ishiba H; Tochiki N; Takahashi A; Kataoka S; Okuda K; Liu Y; Fujii H; Umemura A; Moriguchi M; Okanoue T; Itoh Y
Lab Invest; 2022 Mar; 102(3):281-289. PubMed ID: 34732847
[TBL] [Abstract][Full Text] [Related]
13. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
[TBL] [Abstract][Full Text] [Related]
14. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
16. Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH.
Fredrickson G; Barrow F; Dietsche K; Parthiban P; Khan S; Robert S; Demirchian M; Rhoades H; Wang H; Adeyi O; Revelo XS
Mol Metab; 2021 Nov; 53():101270. PubMed ID: 34118476
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
Sakai Y; Chen G; Ni Y; Zhuge F; Xu L; Nagata N; Kaneko S; Ota T; Nagashimada M
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32790863
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
19. Sugar kelp (Saccharina latissima) inhibits hepatic inflammation and fibrosis in a mouse model of diet-induced nonalcoholic steatohepatitis.
Kim MB; Lee Y; Bae M; Kang H; Hu S; Pham TX; Lee JY; Park YK
J Nutr Biochem; 2021 Nov; 97():108799. PubMed ID: 34119629
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
[Next] [New Search]